Erratum to: Optimising inhaled mannitol for cystic fibrosis in an adult population (Breathe, (2015), 11, (39–48), 10.1183/20734735.021414));Optimising inhaled mannitol for cystic fibrosis in an adult population

Breathe

Volumn 11, Issue 1, 2015, Pages 39-48

  Flume, Patrick A ^a   Aitken, Moira L ^b   Bilton, Diana ^c   Agent, Penny ^c   Charlton, Brett ^d   Forster, Emma ^e   Fox, Howard G ^d   Hebestreit, Helge ^f   Kolbe, John ^g   Zuckerman, Jonathan B ^h   Button, Brenda M ⁱ  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d Pharmaxis Ltd   (Australia)

^e BRISTOL ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MANNITOL;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY POWDER; FEMALE; HEADACHE; HEMOPTYSIS; HUMAN; INTESTINE OBSTRUCTION; LOWER RESPIRATORY TRACT INFECTION; LUNG CLEARANCE; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUCOCILIARY CLEARANCE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; RHINOPHARYNGITIS; SECRETION (PROCESS); SORE THROAT; TREATMENT DURATION; VISCOELASTICITY;

EID: 84925177481     PISSN: 18106838     EISSN: 20734735     Source Type: Journal    
DOI: 10.1183/20734735.112315     Document Type: Erratum

References (19)

1. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071–1080.
2. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185: 645–652.
3. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care 2009; 54: 618–627.
4. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Int Med 2007; 261: 5–16.
5. Flume PA, Robinson KA, O’Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009; 54: 522–537.
6. Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957–969.
7. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188–9192.
8. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006; 354: 291–293.
9. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241–250.
10. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900–903.
11. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 2006; 12: 445–452.
12. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009; CD001506.
13. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358: 1316–1321.
14. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14: 678–685.
15. Hurt K, Bilton D. Inhaled mannitol for the treatment of cystic fibrosis. Expert Rev Respir Med 2012; 6: 19–26.
16. Daviskas E, Rubin BK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med 2013; 7: 65–75.
17. Pettit RS, Johnson CE. Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother 2011; 45: 49–59.
18. Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013; 12: 367–376.
19. Button BM, Finlayson F, Borg B, et al. Clinical impact of inhaled mannitol in an adult cystic fibrosis population. J Cyst Fibros 2013; 1: S98.